Producing, Controlling and Stabilizing Pasteur's Anthrax Vaccine
Producing, Controlling and Stabilizing Pasteur’s Anthrax Vaccine: Creating a New Industry and a Health Market Maurice Cassier To cite this version: Maurice Cassier. Producing, Controlling and Stabilizing Pasteur’s Anthrax Vaccine: Creating a New Industry and a Health Market. Science in Context, Cambridge University Press (CUP), 2008. halshs- 01894157 HAL Id: halshs-01894157 https://halshs.archives-ouvertes.fr/halshs-01894157 Submitted on 23 Dec 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Vol. 21, No. 2 Producing, Controlling and Stabilizing Pasteur’s Anthrax Vaccine: Creating a New Industry and a Health Market Maurice Cassier CNRS Argument When Pasteur and Chamberland hastily set up their small biological industry to meet the agricultural demand for the anthrax vaccine, their methods for preparation and production had not yet been stabilized. The process of learning how to standardize biological products was accelerated in 1882 when vaccination accidents required the revision of production norms as the first hypotheses on fixity, inalterability, and transportability of vaccines were invalidated and replaced by procedures for continuous monitoring of the calibration of vaccines and the renewal of vaccine strains. Initially, the incompleteness and ongoing development of production standards justified Pasteur’s monopoly on the production of the anthrax vaccine under his immediate supervision.
[Show full text]